KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 4605 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Intranasal Carbetocin Reduces Hyperphagia, Anxiousness, and Distress in Prader-Willi Syndrome: CARE-PWS Phase 3 Trial. PMID 36633570 · J Clin Endocrinol Metab · 2023-Jun-16 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. PMID 36848639 · Blood Adv · 2023-Jun-13 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China. PMID 37301827 · Lipids Health Dis · 2023-Jun-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. PMID 37156252 · Lancet · 2023-Jun-10 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial. PMID 37104723 · J Clin Oncol · 2023-Jun-10 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial. PMID 37365597 · Radiat Oncol · 2023-Jun-09 The study is an eligible Phase III RCT with a drug intervention, but its primary endpoint is hematological toxicity (a safety/toxicity endpoint), not a time-to-event efficacy endpoint required for the cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Oral micronized progesterone for perimenopausal night sweats and hot flushes a Phase III Canada-wide randomized placebo-controlled 4 month trial. PMID 37277418 · Sci Rep · 2023-Jun-05 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial. PMID 37146623 · Lancet · 2023-Jun-03 The study is a randomized, phase 3 clinical trial for chronic low back pain, not an oncology trial. It does not involve a drug-containing intervention and does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Association of circulating markers with cognitive decline after radiation therapy for brain metastasis. PMID 36472389 · Neuro Oncol · 2023-Jun-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. PMID 37074705 · JAMA Dermatol · 2023-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial. PMID 37036722 · JAMA Neurol · 2023-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ciprofol vs. propofol for the induction and maintenance of general anaesthesia: A multicentre, single-blind, randomised, parallel-group, phase 3 clinical trial. PMID 36647565 · Eur J Anaesthesiol · 2023-Jun-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION). PMID 37408283 · Endocrinol Metab (Seoul) · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment. PMID 37352322 · PLoS Negl Trop Dis · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial. PMID 37328272 · BMJ Open Diabetes Res Care · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. PMID 37291210 · Nat Med · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial. PMID 37245897 · Heart Rhythm · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. PMID 37210099 · Lancet Neurol · 2023-Jun The trial is for Huntington's disease, not oncology. The primary efficacy endpoint is a change in chorea symptom score (UHDRS TMC), which is not a time-to-event outcome (OS, PFS, DFS, etc.) or Kaplan-Meier analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. PMID 37210098 · Lancet Neurol · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial. PMID 37182529 · Lancet Public Health · 2023-Jun The trial meets criteria for human, randomized, phase 3, original-result oncology study, but it is excluded because: 1) The primary efficacy endpoint is 'cervical cancer screening uptake' (a binary proportion at 6 months), not a time-to-event endpoint like OS, PFS, DFS, etc., nor is it analyzed with Kaplan-Meier or reported as a hazard ratio. 2) The intervention is a screening diagnostic tool (HPV self-collection kit) with scheduling assistance, not a drug-containing therapeutic intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. PMID 37167996 · Lancet HIV · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. PMID 37148899 · Lancet Diabetes Endocrinol · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial. PMID 37139642 · United European Gastroenterol J · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India. PMID 37093266 · Cancer Chemother Pharmacol · 2023-Jun Study meets criteria for oncology, human, randomized, Phase 3, and drug intervention, but the primary efficacy endpoint is ORR (a response rate), not a time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP). No time-to-event signal is present in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes. PMID 37017631 · Clin Pharmacol Ther · 2023-Jun The study is a randomized, Phase III clinical trial with a drug intervention (molnupiravir) and reports original results. However, the study addresses COVID-19, which is not a human malignant neoplasm (cancer), and the primary efficacy endpoint is hospitalization risk (logistic regression, odds ratio), not a time-to-event outcome (e.g., OS, PFS, DFS) analyzed with Kaplan-Meier or hazard ratios.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial. PMID 36877527 · Am J Hematol · 2023-Jun 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L B
旧查询独有 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation. PMID 36822371 · Gastroenterology · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Accurate tumor segmentation and treatment outcome prediction with DeepTOP. PMID 36813177 · Radiother Oncol · 2023-Jun The record describes a methodological study using data from a Phase III randomized trial to develop and validate a deep learning tool for tumor segmentation and predicting pathological complete response. While the underlying trial is a randomized Phase III oncology trial, this specific report does not present trial efficacy results with a time-to-event endpoint (e.g., OS, PFS). The endpoint reported is pathological complete response, a binary outcome, not a time-to-event endpoint. Additionally, no specific drug intervention is named; the abstract only mentions 'chemo/radiotherapy'. Therefore, it does not meet the criteria for inclusion as an original formal-result report with a primary/key secondary time-to-event efficacy endpoint.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. PMID 36782093 · Diabetes Obes Metab · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Traditional Vietnamese medicine Kovir capsule for non-severe COVID-19 patients: A phase III double-blind randomized controlled trial. PMID 36751127 · Phytother Res · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials. PMID 36725056 · J Rheumatol · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
An analysis of feasibility of robotic colectomy: post hoc analysis of a phase III randomised controlled trial. PMID 36525149 · J Robot Surg · 2023-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial. PMID 35793833 · Thorax · 2023-Jun 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in Japanese healthy infants: A phase III study (V114-033). PMID 37344262 · Vaccine · 2023-Jul-31 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. PMID 37356066 · N Engl J Med · 2023-Jul-27 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
[Comparison of the effects and safety of dydrogesterone and medroxyprogesterone acetate on endometrial hyperplasia without atypia: a randomized controlled non-inferior phase Ⅲ clinical study]. PMID 37474326 · Zhonghua Fu Chan Ke Za Zhi · 2023-Jul-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. PMID 37272521 · N Engl J Med · 2023-Jul-20 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Safety and efficacy of the FAKHRAVAC compared with BBIBP-Corv2 against SARS-CoV-2 in adults: a non-inferiority multi-center trial. PMID 37464440 · Virol J · 2023-Jul-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. PMID 37354562 · JAMA · 2023-Jul-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. PMID 37268435 · Neurology · 2023-Jul-18 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of mindfulness added to treatment as usual in patients with chronic migraine and medication overuse headache: a phase-III single-blind randomized-controlled trial (the MIND-CM study). PMID 37452281 · J Headache Pain · 2023-Jul-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. PMID 36734148 · J Clin Endocrinol Metab · 2023-Jul-14 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). PMID 36999560 · Br J Dermatol · 2023-Jul-07 The study is a Phase III randomized trial of a drug (baricitinib) for atopic dermatitis, which is a non-oncologic inflammatory skin condition, not a malignant neoplasm. The primary and key secondary endpoints are categorical response rates (e.g., vIGA, EASI, SCORAD) and continuous mean changes, not time-to-event efficacy endpoints like OS, PFS, DFS, or Kaplan-Meier curves with hazard ratios.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. PMID 37345876 · N Engl J Med · 2023-Jul-06 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors. PMID 37141403 · Oncologist · 2023-Jul-05 The report is an eligible Phase III randomized drug-intervention oncology trial, but it does not meet the required time-to-event efficacy endpoint criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment of Idiopathic Recurrent Pericarditis With Goflikicept: Phase II/III Study Results. PMID 37380301 · J Am Coll Cardiol · 2023-Jul-04 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischemic Stroke Within 4.5 Hours of Stroke Onset: A Phase 3 Randomized Clinical Trial. PMID 37490291 · JAMA Netw Open · 2023-Jul-03 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact. PMID 37499085 · Medicine (Baltimore) · 2023-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis. PMID 37480206 · Allergy Asthma Proc · 2023-Jul-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and Tolerability of V114 Pneumococcal Vaccine in Infants: A Phase 3 Study. PMID 37309607 · Pediatrics · 2023-Jul-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -